• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis.

作者信息

Konigsberg W, Kirchhofer D, Riederer M A, Nemerson Y

机构信息

The Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, USA.

出版信息

Thromb Haemost. 2001 Sep;86(3):757-71.

PMID:11583305
Abstract
摘要

相似文献

1
The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis.
Thromb Haemost. 2001 Sep;86(3):757-71.
2
The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling?组织因子的多效性作用：因子VIIa诱导的细胞内信号传导的潜在作用？
Thromb Haemost. 2001 Dec;86(6):1353-9.
3
The structural basis of function of the TF. VIIa complex in the cellular initiation of coagulation.凝血因子VIIa复合物在细胞内凝血起始过程中发挥功能的结构基础。
Thromb Haemost. 1997 Jul;78(1):401-5.
4
The factor VIIa/tissue factor complex.凝血因子VIIa/组织因子复合物
Thromb Haemost. 1997 Jul;78(1):512-5.
5
The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor.凝血因子VIIa与可溶性组织因子复合物的晶体结构
Nature. 1996 Mar 7;380(6569):41-6. doi: 10.1038/380041a0.
6
Tissue factor: an enzyme cofactor and a true receptor.组织因子：一种酶辅因子和一种真正的受体。
Thromb Haemost. 2001 Jul;86(1):66-74.
7
A new paradigm for blood coagulation research.血液凝固研究的新范式。
Thromb Haemost. 2000 Apr;83(4):520, 522.
8
Selective attenuation of the extrinsic limb of the tissue factor-driven coagulation protease cascade by occupancy of a novel peptidyl docking site on tissue factor.通过占据组织因子上一个新的肽基对接位点，对组织因子驱动的凝血蛋白酶级联反应的外源性途径进行选择性衰减。
Biochemistry. 2003 Sep 16;42(36):10619-26. doi: 10.1021/bi034910f.
9
Structure and biology of tissue factor pathway inhibitor.组织因子途径抑制剂的结构与生物学特性
Thromb Haemost. 2001 Oct;86(4):959-72.
10
Big rigs in blood coagulation.
Nature. 1996 Mar 7;380(6569):21-3. doi: 10.1038/380021a0.

引用本文的文献

1
From immune dysregulation to organ dysfunction: understanding the enigma of Sepsis.从免疫失调到器官功能障碍：解读脓毒症之谜。
Front Microbiol. 2024 Aug 26;15:1415274. doi: 10.3389/fmicb.2024.1415274. eCollection 2024.
2
Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.肺癌骨转移的预测和预后生物标志物及其治疗价值。
Front Oncol. 2021 Oct 14;11:692788. doi: 10.3389/fonc.2021.692788. eCollection 2021.
3
Hemostatic Testing in Critically Ill Infants and Children.危重症婴幼儿和儿童的止血检测
Front Pediatr. 2021 Jan 8;8:606643. doi: 10.3389/fped.2020.606643. eCollection 2020.
4
Down-regulation of tissue factor inhibits invasion and metastasis of non-small cell lung cancer.组织因子的下调抑制非小细胞肺癌的侵袭和转移。
J Cancer. 2020 Jan 1;11(5):1195-1202. doi: 10.7150/jca.37321. eCollection 2020.
5
Psychological factors and DNA methylation of genes related to immune/inflammatory system markers: the VA Normative Aging Study.心理因素与免疫/炎症系统标志物相关基因的DNA甲基化：退伍军人事务部标准老化研究
BMJ Open. 2016 Jan 5;6(1):e009790. doi: 10.1136/bmjopen-2015-009790.
6
Tissue factor as a novel target for treatment of breast cancer.组织因子作为治疗乳腺癌的新靶点。
Oncologist. 2013;18(1):14-8. doi: 10.1634/theoncologist.2012-0322. Epub 2013 Jan 3.
7
Unexpected origins of the enhanced pairing affinity of 2'-fluoro-modified RNA.2'-氟修饰 RNA 增强配对亲和力的意外起源。
Nucleic Acids Res. 2011 Apr;39(8):3482-95. doi: 10.1093/nar/gkq1270. Epub 2010 Dec 22.
8
The pathogenesis of sepsis.脓毒症的发病机制。
Annu Rev Pathol. 2011;6:19-48. doi: 10.1146/annurev-pathol-011110-130327.
9
Cystine 186-cystine 209 disulfide bond is not essential for the procoagulant activity of tissue factor or for its de-encryption.胱氨酸 186-胱氨酸 209 二硫键对于组织因子的促凝活性或其去加密并非必需。
Blood. 2010 May 27;115(21):4273-83. doi: 10.1182/blood-2009-09-241356. Epub 2010 Mar 17.
10
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.沙利度胺治疗难治性子宫内膜癌患者的II期试验及与血管生成生物标志物的相关性：一项妇科肿瘤学组研究
Gynecol Oncol. 2007 May;105(2):508-16. doi: 10.1016/j.ygyno.2007.01.019. Epub 2007 Feb 15.